Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan, A.R.; Touchard, S.; Leckey, C.; O'Hagan, C.; Nevado-Holgado, A.J.; Barkhof, F.; Bertram, L.; Blin, O.; Bos, I.; Dobricic, V.; Engelborghs, S.; Frisoni, G.; Frölich, L.; Gabel, S.; Johannsen, P.; Kettunen, P.; Kłoszewska, I.; Legido-Quigley, C.; Lleó, A.; Martinez-Lage, P.; Mecocci, P.; Meersmans, K.; Molinuevo, J.L.; Peyratout, G.; Popp, J.; Richardson, J.; Sala, I.; Scheltens, P.; Streffer, J.; Soininen, H.; Tainta-Cuezva, M.; Teunissen, C.; Tsolaki, M.; Vandenberghe, R.; Visser, P.J.; Vos, S.; Wahlund, L.O.; Wallin, A.; Westwood, S.; Zetterberg, H.; Lovestone, S.; Morgan, B.P.

doi:10.1016/j.jalz.2019.03.007

Inflammatory biomarkers in Alzheimer's disease plasma.

Details

Download: 31047856.pdf (1114.03 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0

Serval ID

serval:BIB_E5F2C092E354

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

Inflammatory biomarkers in Alzheimer's disease plasma.

Journal

Alzheimer's & dementia

Author(s)

Morgan A.R., Touchard S., Leckey C., O'Hagan C., Nevado-Holgado A.J., Barkhof F., Bertram L., Blin O., Bos I., Dobricic V., Engelborghs S., Frisoni G., Frölich L., Gabel S., Johannsen P., Kettunen P., Kłoszewska I., Legido-Quigley C., Lleó A., Martinez-Lage P., Mecocci P., Meersmans K., Molinuevo J.L., Peyratout G., Popp J., Richardson J., Sala I., Scheltens P., Streffer J., Soininen H., Tainta-Cuezva M., Teunissen C., Tsolaki M., Vandenberghe R., Visser P.J., Vos S., Wahlund L.O., Wallin A., Westwood S., Zetterberg H., Lovestone S., Morgan B.P.

Working group(s)

NIMA Consortium, Annex: NIMA-Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease

Contributor(s)

Bullmore E.T., Bhatti J., Chamberlain S.J., Correia M.M., Crofts A.L., Dickinson A., Foster A.C., Kitzbichler M.G., Knight C., Lynall M.E., Maurice C., O'Donnell C., Pointon L.J., St George Hyslop P., Turner L., Vertes P., Widmer B., Williams G.B., Morgan B.P., Leckey C.A., Morgan A.R., O'Hagan C., Touchard S., Cavanagh J., Deith C., Farmer S., McClean J., McColl A., McPherson A., Scouller P., Sutherland M., Boddeke HWGM, Richardson J.C., Khan S., Murphy P., Parker C.A., Patel J., Jones D., de Boer P., Kemp J., Drevets W.C., Nye J.S., Wittenberg G., Isaac J., Bhattacharya A., Carruthers N., Kolb H., Pariante C.M., Turkheimer F., Barker G.J., Byrom H., Cash D., Cattaneo A., Gee A., Hastings C., Mariani N., McLaughlin A., Mondelli V., Nettis M., Nikkheslat N., Randall K., Sheridan H., Simmons C., Singh N., Van Loo V., Vicente-Rodriguez M., Wood T.C., Worrell C., Zajkowska Z., Plath N., Egebjerg J., Eriksson H., Gastambide F., Adams K.H., Jeggo R., Thomsen C., Pederson J.T., Campbell B., Möller T., Nelson B., Zorn S., O'Connor J., Attenburrow M.J., Baird A., Benjamin J., Clare S., Cowen P., Huang I.D., Hurley S., Jones H., Lovestone S., Mada F., Nevado-Holgado A., Oladejo A., Ribe E., Smith K., Vyas A., Hughes Z., Balice-Gordon R., Duerr J., Piro J.R., Sporn J., Perry V.H., Cleal M., Fryatt G., Gomez-Nicola D., Mancuso R., Reynolds R., Harrison N.A., Cercignani M., Clarke C.L., Hoskins E., Kohn C., Murray R., Wilcock L., Wlazly D., Mount H.

ISSN

1552-5279 (Electronic)

ISSN-L

1552-5260

Publication state

Published

Issued date

06/2019

Peer-reviewed

Oui

Volume

Number

Pages

776-787

Language

english

Notes

Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Abstract

Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.
A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.
Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).
Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Keywords

Aged, Alzheimer Disease/blood, Alzheimer Disease/diagnosis, Amyloid beta-Peptides/blood, Biomarkers/blood, Cognitive Dysfunction/blood, Cognitive Dysfunction/diagnosis, Cohort Studies, Complement Factor B, Complement Factor H, Humans, Inflammation, Internationality, Prognosis, Alzheimer's disease, Biomarker, Complement, Plasma

URN

urn:nbn:ch:serval-BIB_E5F2C092E3542

OAI-PMH

oai:serval.unil.ch:BIB_E5F2C092E354

DOI

10.1016/j.jalz.2019.03.007

Pubmed

31047856

Web of science

000470084500005

Open Access

Yes